DDW: Cannabinoid use increases sedation requirements during endoscopy – Consumer Health News

THURSDAY, May 26, 2022 (HealthDay News) — Basic cannabinoid use is associated with higher sedation use during endoscopy with endoscopist-directed conscious sedation, according to a study presented at Digestive Diseases Week 2022, which was held from May 21 to 24 in San Diego.

Yasmin Nasser, MD, Ph.D., of the University of Calgary in Alberta, Canada, and colleagues prospectively assessed the association between initial cannabinoid use and sedation requirements for esophagogastroduodenoscopy ( EGD) and colonoscopy in 419 adult outpatients.

Researchers found that baseline cannabinoid use was associated with high midazolam use (≥ 5 mg) during EGD (adjusted odds ratio [aOR], 2.89; 95% confidence interval [CI], 1.19 to 7.50) but not during colonoscopy (aOR 0.89; 95% CI, 0.41 to 1.91). There was an association between initial cannabinoid use and administration of any diphenhydramine during EGD (aOR, 3.04; 95% CI, 1.29 to 7.30), with a nonsignificant trend observed for colonoscopy (aOR, 2.36; 95% CI, 0.81 to 7.04). There was also an association between initial cannabinoid use and an increased likelihood of requiring high total sedation (midazolam ≥ 5 mg, fentanyl ≥ 100 mcg, or any diphenhydramine during EGD; aOR, 3.72; 95 CI %, 1.35 to 11.68). No independent association was observed between cannabinoid use and fentanyl use or adverse events, nor was it associated with consciousness or intra-procedural discomfort, according to scores on the scale reported by patients. patients for the tolerability of endoscopic procedures.

“Given the increasingly widespread use of cannabinoids, endoscopists should be equipped with optimal sedation strategies for this population,” the authors write.

Press release

More information

Comments are closed.